Wugen
Matthew Cooper has worked for WUGEN since 2018, where they currently serve as Chief Scientific Officer. Prior to this, they were employed at Washington University School of Medicine in St. Louis from 2011 to 2018, during which time they held the roles of Assistant Professor, Instructor in Medicine and Postdoctoral Research Associate.
Matthew Cooper received a Bachelor of Science degree from the University of Surrey in 2004. Matthew then went on to pursue a Doctor of Philosophy degree in Cancer Genetics from the same university.
Wugen
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.